Covered recipient · General Payments record
BRIAN E LEWIS
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$315.41
13 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $315.41 | 13 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $86.96 | 4 |
| Merck Sharp & Dohme LLC | $50.42 | 1 |
| Gilead Sciences, Inc. | $50.25 | 2 |
| Celgene Corporation | $32.17 | 2 |
| Daiichi Sankyo Inc. | $27.86 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $25.52 | 1 |
| Eisai Inc. | $24.77 | 1 |
| Tempus AI, Inc | $17.46 | 1 |
Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRIAN E LEWIS
NPI 1871773705 · CMS profile ID 1185195
Allopathic & Osteopathic Physicians / Internal Medicine
NEW ORLEANS, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
13 matching records · $315.41 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–13 of 13.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $26.84 | 11/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133763064 | CMS |
| Merck Sharp & Dohme LLC | $50.42 | 11/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141686325 | CMS |
| Astellas Pharma US Inc | $13.90 | 11/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139445248 | CMS |
| Celgene Corporation | $15.69 | 11/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101116280 | CMS |
| Celgene Corporation | $16.48 | 11/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101116278 | CMS |
| Astellas Pharma US Inc | $26.90 | 08/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139347242 | CMS |
| Tempus AI, Inc | $17.46 | 06/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150168516 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $25.52 | 06/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139164256 | CMS |
| Gilead Sciences, Inc. | $23.41 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133763062 | CMS |
| Astellas Pharma US Inc | $29.57 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139354975 | CMS |
| Astellas Pharma US Inc | $16.59 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139324030 | CMS |
| Daiichi Sankyo Inc. | $27.86 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089448692 | CMS |
| Eisai Inc. | $24.77 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110734659 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,270.00 | 2 |
| PY2025 | Principal investigator | $333,143.56 | 79 |
| PY2024 | Recipient | $1,993.89 | 3 |
| PY2024 | Principal investigator | $405,724.59 | 16 |
| PY2023 | Principal investigator | $899,284.11 | 32 |
| PY2022 | Principal investigator | $114,917.88 | 36 |
| PY2021 | Principal investigator | $13,252.00 | 2 |
| PY2020 | Principal investigator | $142,805.58 | 3 |
| PY2019 | Principal investigator | $60,217.32 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,406.40 | 12/31/2023 | Non-covered Recipient Entity Tulane Cancer Center | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1042499053 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,325.48 | 12/31/2023 | Non-covered Recipient Entity Tulane University School of Medicine | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer KEYNOTE-905,EV-303 | No dispute reported | 06/30/2026 | 1042510821 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $25,594.79 | 12/31/2023 | Non-covered Recipient Entity Tulane University School of Medicine | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 1042535099 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $613.60 | 12/31/2023 | Non-covered Recipient Entity Tulane University School of Medicine | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 1042535107 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $118.55 | 10/02/2023 | Non-covered Recipient Entity TULANE UNIVERSITY SCHOOL OF MEDICINE | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049072833 |
| Principal investigator 1 | Seagen Inc. | $820.00 | 09/20/2023 | Non-covered Recipient Entity TULANE UNIVERSITY SCHOOL OF MEDICINE | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer | No dispute reported | 06/30/2026 | 995868557 |
| Principal investigator 1 | Genentech, Inc. | $10,899.55 | 08/16/2023 | Non-covered Recipient Entity ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND TULANE CANCER CTR | Phase III study in Adjuvant therapy in Renal Cell Carcinoma patients | No dispute reported | 06/30/2026 | 1040221619 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $118.55 | 07/03/2023 | Non-covered Recipient Entity TULANE UNIVERSITY SCHOOL OF MEDICINE | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049072813 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $118.55 | 07/03/2023 | Non-covered Recipient Entity TULANE UNIVERSITY SCHOOL OF MEDICINE | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049072823 |
| Principal investigator 1 | Seagen Inc. | $820.00 | 06/20/2023 | Non-covered Recipient Entity TULANE UNIVERSITY SCHOOL OF MEDICINE | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer | No dispute reported | 06/30/2026 | 995868543 |
| Principal investigator 1 | Janssen Research & Development, LLC | $121.00 | 05/05/2023 | Non-covered Recipient Entity ADMINISTRATORS OF THE TULANE EDUCAT IONAL FUND | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 986154753 |
| Principal investigator 1 | Janssen Research & Development, LLC | $121.00 | 05/05/2023 | Non-covered Recipient Entity ADMINISTRATORS OF THE TULANE EDUCAT IONAL FUND | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 986154755 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $785.87 | 04/25/2023 | Non-covered Recipient Entity TULANE CANCER CENTER OFFICE OF CLINICAL RESEARCH | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1017194429 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 04/20/2023 | Non-covered Recipient Entity The Administrators Of The Tulane Educational Fund Dba On Behalfof Tulane University | Research Agreement - Tulane Educational Fund d/b/a Tulane University | No dispute reported | 06/30/2026 | 1000195015 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $128,146.17 | 04/13/2023 | Non-covered Recipient Entity TULANE CANCER CENTER OFFICE OF CLINICAL RESEARCH | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1017227207 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,557.57 | 03/08/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049061953 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,961.01 | 03/08/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062525 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,703.37 | 03/08/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062887 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,026.00 | 02/10/2023 | Non-covered Recipient Entity Tulane University | Phase III Adjuvant Bladder (nivo mono) | No dispute reported | 06/30/2026 | 1027474997 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,557.57 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049061315 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,557.57 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049061520 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,221.02 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049061709 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,703.37 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049061805 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,557.57 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062375 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,221.02 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062409 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,961.01 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062441 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,557.57 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062599 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,221.02 | 01/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062673 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $383,003.88 | 01/26/2023 | Non-covered Recipient Entity TULANE UNIVERSITY HEALTH SCIENCES CENTER | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1017205059 |
| Principal investigator 1 | Seagen Inc. | $820.00 | 01/10/2023 | Non-covered Recipient Entity TULANE UNIVERSITY SCHOOL OF MEDICINE | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer | No dispute reported | 06/30/2026 | 995868527 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $219,980.43 | 01/09/2023 | Non-covered Recipient Entity ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1017233027 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $66,664.62 | 01/09/2023 | Non-covered Recipient Entity ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1017234633 |